TY - JOUR
T1 - The declining use of axillary dissection in patients with early stage breast cancer
AU - Du, Xianglin
AU - Freeman, Jean L.
AU - Goodwin, James S.
N1 - Funding Information:
This study was supported by grants from the Department of Defense (DAMD17-97-1-709-5) and the National Cancer Institute (CA72076). The authors acknowledge the efforts of the SEER Program tumor registries in the creation of the SEER public-use database. The interpretation and reporting of these data are the sole responsibilities of the authors.
Copyright:
Copyright 2007 Elsevier B.V., All rights reserved.
PY - 1999
Y1 - 1999
N2 - Objectives: To determine any changes in usage of axillary dissection over time from 1983 to 1993, and to characterize those patients who do not receive axillary node dissection. Methods: A total of 129,946 female patients receiving cancer-directed surgery for early stage breast cancer, who were identified from the SEER (Surveillance, Epidemiology and End Results) program and diagnosed from 1983 to 1993, were included in the study. The surgical treatment and axillary dissection were based on treatment data collected by the SEER during the first course of therapy. Logistic regression analyses were used to assess the effect of patient and tumor characteristics on the likelihood of not receiving different types of treatment. Results: The percentage of women not receiving axillary dissection has increased over time, from 14.4% in 1983 to 16.8% in 1993. Nearly a quarter of women undergoing breast conserving surgery for local stage breast cancer receive neither axillary dissection nor radiotherapy. Older, unmarried, and non-white women and those with very small (< 0.5 cm) or very large (> 4 cm) tumors were most likely to receive neither axillary node dissection nor irradiation. Among those not receiving axillary dissection, 42% had tumors 1-3 cm in size and were not receiving radiation therapy. Conclusions: There is an apparent divergence between the type of patient who has been recommended as an appropriate candidate for avoiding axillary dissection (those with small tumors and those who will receive adjuvant therapy) and those who are actually not receiving axillary dissection in the community.
AB - Objectives: To determine any changes in usage of axillary dissection over time from 1983 to 1993, and to characterize those patients who do not receive axillary node dissection. Methods: A total of 129,946 female patients receiving cancer-directed surgery for early stage breast cancer, who were identified from the SEER (Surveillance, Epidemiology and End Results) program and diagnosed from 1983 to 1993, were included in the study. The surgical treatment and axillary dissection were based on treatment data collected by the SEER during the first course of therapy. Logistic regression analyses were used to assess the effect of patient and tumor characteristics on the likelihood of not receiving different types of treatment. Results: The percentage of women not receiving axillary dissection has increased over time, from 14.4% in 1983 to 16.8% in 1993. Nearly a quarter of women undergoing breast conserving surgery for local stage breast cancer receive neither axillary dissection nor radiotherapy. Older, unmarried, and non-white women and those with very small (< 0.5 cm) or very large (> 4 cm) tumors were most likely to receive neither axillary node dissection nor irradiation. Among those not receiving axillary dissection, 42% had tumors 1-3 cm in size and were not receiving radiation therapy. Conclusions: There is an apparent divergence between the type of patient who has been recommended as an appropriate candidate for avoiding axillary dissection (those with small tumors and those who will receive adjuvant therapy) and those who are actually not receiving axillary dissection in the community.
KW - Axillary node dissection
KW - Breast cancer
KW - Cancer-directed surgery
KW - Radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=0032928308&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032928308&partnerID=8YFLogxK
U2 - 10.1023/A:1006170811237
DO - 10.1023/A:1006170811237
M3 - Article
C2 - 10326790
AN - SCOPUS:0032928308
SN - 0167-6806
VL - 53
SP - 137
EP - 144
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 2
ER -